JP2018523665A - 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体 - Google Patents

抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体 Download PDF

Info

Publication number
JP2018523665A
JP2018523665A JP2018506115A JP2018506115A JP2018523665A JP 2018523665 A JP2018523665 A JP 2018523665A JP 2018506115 A JP2018506115 A JP 2018506115A JP 2018506115 A JP2018506115 A JP 2018506115A JP 2018523665 A JP2018523665 A JP 2018523665A
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018506115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523665A5 (enExample
Inventor
リロイ タウンゼント
リロイ タウンゼント
ジョン ドラック
ジョン ドラック
ロイ ダブリュ． ウェア
ロイ ダブリュ． ウェア
ジョン ヘンリー ザ サード ブーゲル
ジョン ヘンリー ザ サード ブーゲル
ラママーティー ブイ エス チャンガルバラ
ラママーティー ブイ エス チャンガルバラ
アーロン リー ダウニー
アーロン リー ダウニー
アーネスト ランドール ジュニア ラニアー
アーネスト ランドール ジュニア ラニアー
アンドリュー ルイス マクアイヴァー
アンドリュー ルイス マクアイヴァー
ブラッドリー デビッド ロバートソン
ブラッドリー デビッド ロバートソン
ディーン ウォレス セレセス
ディーン ウォレス セレセス
フィロゼ ベーラム セスナ
フィロゼ ベーラム セスナ
Original Assignee
キメリックス インコーポレイテッド
キメリックス インコーポレイテッド
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キメリックス インコーポレイテッド, キメリックス インコーポレイテッド, ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン, ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン filed Critical キメリックス インコーポレイテッド
Publication of JP2018523665A publication Critical patent/JP2018523665A/ja
Publication of JP2018523665A5 publication Critical patent/JP2018523665A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
JP2018506115A 2015-08-06 2016-08-08 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体 Withdrawn JP2018523665A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562202010P 2015-08-06 2015-08-06
US62/202,010 2015-08-06
GB1606645.8 2016-04-15
GB201606645 2016-04-15
PCT/US2016/046056 WO2017024310A1 (en) 2015-08-06 2016-08-08 Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents

Publications (2)

Publication Number Publication Date
JP2018523665A true JP2018523665A (ja) 2018-08-23
JP2018523665A5 JP2018523665A5 (enExample) 2019-09-19

Family

ID=57943734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506115A Withdrawn JP2018523665A (ja) 2015-08-06 2016-08-08 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体

Country Status (11)

Country Link
US (6) US9708359B2 (enExample)
EP (1) EP3331895B1 (enExample)
JP (1) JP2018523665A (enExample)
KR (1) KR102630013B1 (enExample)
CN (1) CN108026136A (enExample)
AU (1) AU2016301188A1 (enExample)
BR (1) BR112018002399A2 (enExample)
EA (1) EA201890454A1 (enExample)
MX (1) MX2018001073A (enExample)
PH (1) PH12018500263A1 (enExample)
WO (1) WO2017024310A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538442A (ja) * 2020-08-24 2023-09-07 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
ES2792899T3 (es) * 2015-02-24 2020-11-12 Pfizer Derivados de nucleósidos sustituidos útiles como agentes anticancerosos
US10472364B2 (en) * 2016-09-09 2019-11-12 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
JP7016170B2 (ja) * 2016-12-16 2022-02-04 国立大学法人東海国立大学機構 ヌクレオシド誘導体及びその利用
US20200115404A1 (en) * 2017-03-31 2020-04-16 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
ES3011607T3 (en) 2017-09-21 2025-04-07 Chimerix Inc Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide and uses thereof
CA3080896A1 (en) 2017-10-31 2019-05-09 Yamasa Corporation Nucleoside derivative and use thereof
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
BR112020018209A2 (pt) * 2018-03-07 2020-12-29 Emory University Composições farmacêuticas, recipiente pressurizado, e, métodos para tratar ou prevenir uma infecção viral e para tratar ou prevenir um coronavírus humano, coronavírus sars, coronavírus mers, vírus da encefalite equina oriental, vírus da encefalite equina ocidental, vírus da encefalite equina venezuelana, vírus da chicungunha, vírus ross river, rsv, vírus influenza a, vírus influenza b, vírus tacaribe, vírus pichinde, vírus junin, vírus da febre lassa, vírus da cariomeningite linfocitária, vírus da febre rift valley, vírus punta toro, vírus lacrosse, vírus maporal, vírus heartland, e vírus da síndrome de trombocitopenia de febre severa, poliovírus, vírus de coxsackie, infecção de norovírus ou enterovírus em um paciente
CN114502172A (zh) 2019-08-22 2022-05-13 爱默蕾大学 核苷前药及其相关用途
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (en) 2020-02-18 2025-09-17 Gilead Sciences, Inc. Antiviral compounds
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
JP2023517579A (ja) * 2020-03-09 2023-04-26 オルガンズ ティシューズ リジェネレーション リパレーション レムプレースメント － オーティーアール３ 呼吸器系の病変の治療のための組成物
WO2021211759A1 (en) * 2020-04-14 2021-10-21 Oyagen, Inc. Method for treating poxviridae infections
US20240207299A1 (en) * 2021-03-29 2024-06-27 Chimerix, Inc. Pyrrolopyrimidine nucleosides for treating or preventing a sars-cov-2 infection
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
WO2024227159A2 (en) * 2023-04-28 2024-10-31 The Scripps Research Institute 4'-substituted nucleosides and nucleotides as antiviral agents
EP4553080A1 (en) * 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleoside derivatives as antiviral agents against coronaviruses

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
US3423398A (en) 1965-05-10 1969-01-21 Pfizer & Co C Sangivamycin and derivatives thereof
US4140851A (en) 1977-11-21 1979-02-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides
JPS61189225A (ja) 1985-02-15 1986-08-22 Airin:Kk 抗アレルギ−剤
US4892865A (en) 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
WO1992005200A1 (en) 1990-09-18 1992-04-02 Chemex Pharmaceuticals, Inc. Xenobiotic-antibody conjugates
CA2108041A1 (en) 1991-03-29 1992-09-30 Nicholas S. Bodor Targeted drug delivery via mixed phosphate derivatives
US5403843A (en) 1991-08-12 1995-04-04 Takeda Chemical Industries, Ltd. Pyrrolopyrimidinyalglutaminate derivatives and their use
WO1993016094A2 (en) 1992-02-12 1993-08-19 Chromagen, Inc. Applications of fluorescent n-nucleosides and fluorescent structural analogs of n-nucleosides
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9226879D0 (en) 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
JPH08506343A (ja) 1993-02-03 1996-07-09 ジェンシア・インコーポレイテッド リキソフラノシル誘導体を含むアデノシンキナーゼ阻害物質
US5656745A (en) 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
JPH07124252A (ja) 1993-11-07 1995-05-16 Masashi Funayama 化学療法剤を固定化した不溶性担体を用いた、負に帯電した 生理活性物質の吸着、分離および定量方法。
US5834469A (en) 1994-06-09 1998-11-10 Smithkline Beecham Corporation Endothelin receptor antagonists
US5554608A (en) 1994-09-28 1996-09-10 Ahluwalia; Gurpreet S. Inhibition of hair growth
US6051578A (en) 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
CA2256765A1 (en) 1996-06-06 1997-12-11 Novartis Ag 2'-substituted nucleosides and oligonucleotide derivatives
US6468991B1 (en) 1997-01-16 2002-10-22 Cyclis Pharmaceuticals, Inc. Method of treating rhinoviral infections
US5955446A (en) 1997-01-16 1999-09-21 Pentose Pharmaceuticals, Inc. Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
EP1250128A2 (en) 1999-12-16 2002-10-23 Alcon, Inc. Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
KR100385281B1 (ko) 2000-02-15 2003-05-23 이승기 새로운 세포 주기 조절 인자 억제제
EP1149583A3 (en) 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
DZ3487A1 (fr) 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
WO2002069949A2 (en) 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
US20020127593A1 (en) 2001-03-12 2002-09-12 Regents Of The University Of California Fluorescence assay for DNA modifying enzymes
AU2002329970A1 (en) 2001-09-04 2003-03-18 Isis Pharmaceuticals, Inc. Pyrrolo(2,3-d)pyrimidines for inhibiting rna-dependent rna viral polymerase
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
AU2002364216A1 (en) * 2001-12-21 2003-07-15 Micrologix Biotech Inc. Anti-viral 7-deaza l-nucleosides
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
AU2003209045B2 (en) 2002-02-13 2006-12-14 Isis Pharmaceuticals, Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
FR2836995B1 (fr) 2002-03-05 2006-09-22 Centre Nat Rech Scient Utilisation de derives de nucleosides comportant un groupement citrate pour la production d'anticorps ayant une affinite pour des nucleosides triphosphorylees et leurs applications
FR2836996A1 (fr) 2002-03-05 2003-09-12 Centre Nat Rech Scient PRECURSEURS DE TRACEURS IMMUNOLOGIQUES NON-PEPTIDIQUES COMPRENANT UN MOTIF TYROSYL-(X)n-LYSINE-(X)n-TYROSINE, PROCEDE DE PREPARATION ET LEURS APPLICATIONS
US6664266B2 (en) 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
AU2003241621A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
CA2488484A1 (en) 2002-06-27 2004-01-08 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
EP1556399A4 (en) 2002-07-16 2007-09-26 Merck & Co Inc Nucleoside derivatives as inhibitors of RNA-dependent viral RNA polymerase
US7094768B2 (en) 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
KR20050059199A (ko) 2002-09-30 2005-06-17 제네랩스 테크놀로지스, 인코포레이티드 Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
CA2503730C (en) 2002-10-31 2011-10-18 Metabasis Therapeutics, Inc. Cytarabine monophosphate prodrugs
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
US20040175384A1 (en) 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2007038613A2 (en) 2005-09-26 2007-04-05 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US7230007B2 (en) 2003-06-12 2007-06-12 Sanofi-Aventis Deutschland Gmbh Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
EP1689784B1 (en) 2003-11-14 2014-07-16 Children's Medical Center Corporation Self-cleaving ribozymes and uses thereof
US7351827B2 (en) 2003-11-21 2008-04-01 The University Of Connecticut Substituted oxetanes, method of making, and method of use thereof
WO2005060958A1 (en) 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
CN1972696B (zh) 2004-06-24 2010-08-11 默沙东公司 用于治疗rna依赖性rna病毒感染的核苷氨基磷酸芳基酯
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
ES2349358T3 (es) 2004-09-22 2010-12-30 Janssen Pharmaceutica Nv Inhibidores de la interacción entre mdm2 y p53.
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
US20070161644A1 (en) 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
ES2409686T3 (es) 2005-01-25 2013-06-27 Prolexys Pharmaceuticals, Inc. Derivados de quinoxalina como agentes antitumorales
JP5710855B2 (ja) 2005-02-02 2015-04-30 ネクスジェニクス・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 神経線維腫の局所治療
US8207136B2 (en) 2005-04-26 2012-06-26 The Board Of Trustees Of The University Of Illinois Nucleoside compounds and methods of use thereof
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EP1945626B1 (en) 2005-08-25 2011-07-27 Schering Corporation Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
JP2007124252A (ja) 2005-10-27 2007-05-17 Sony Corp 放送受信装置と放送受信方法およびプログラム
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
CN1923171B (zh) 2006-02-24 2010-05-19 济南康泉医药科技有限公司 同载抗癌抗生素及其增效剂的复方抗癌药物缓释剂
CN1923173B (zh) 2006-02-24 2010-05-19 济南康泉医药科技有限公司 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2008021981A2 (en) 2006-08-09 2008-02-21 Nexgenix Pharmaceuticals, Llc. Local treatment of epidermal and dermal hyperproliferative lesions
US20080153903A1 (en) 2006-12-22 2008-06-26 Alcon Manufacturing, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
TW200838550A (en) 2007-02-09 2008-10-01 Novartis Ag Organic compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
US20100129933A1 (en) 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
WO2009059304A2 (en) 2007-11-02 2009-05-07 Taiga Biotechnologies, Inc. Compounds for treating abnormal cellular proliferation
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
AR072906A1 (es) 2008-08-06 2010-09-29 Novartis Ag Nucleosidos modificados utiles como antivirales
US20120014911A1 (en) 2009-01-09 2012-01-19 Serge Fuchs Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor
US8785446B2 (en) 2009-01-17 2014-07-22 Children's Medical Center Corporation Treating post-seizure patients
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
KR20120046099A (ko) 2009-02-04 2012-05-09 유니버시티 오브 조지아 리서치 파운데이션 인코퍼레이티드 섬유화를 억제하고 섬유화 질병을 치료하는 방법
JP2012517443A (ja) 2009-02-06 2012-08-02 アールエフエス ファーマ，エルエルシー 癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ
US8475804B2 (en) 2009-02-20 2013-07-02 U.S. Army Medical Research And Material Command Compositions and methods for treatment of filovirus-mediated diseases
WO2010135520A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
US20120208750A1 (en) 2009-09-29 2012-08-16 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
EP2490688B1 (en) 2009-10-19 2014-10-08 Synta Pharmaceuticals Corp. Combination cancer therapy with hsp90 inhibitory compounds
US20150018301A1 (en) 2009-11-06 2015-01-15 The Johns Hopkins University LRRK-2-Mediated Neuronal Toxicity
WO2011079103A1 (en) 2009-12-23 2011-06-30 Sanofi Spiropiperidine benzylamines as beta-tryptase inhibitors
EP2516428A1 (en) 2009-12-23 2012-10-31 Sanofi Tropinone benzylamines as beta-tryptase inhibitors
WO2011088137A2 (en) 2010-01-12 2011-07-21 H. Lee Moffitt Cancer Center & Research Institute Bad pathway gene signature
CN102191233B (zh) 2010-03-04 2014-06-04 中国人民解放军军事医学科学院毒物药物研究所 新颖的10-23脱氧核酶类似物及其用途
WO2011130599A1 (en) 2010-04-16 2011-10-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates of adenine nucleoside analogs
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
ES2524398T3 (es) 2010-07-19 2014-12-09 Gilead Sciences, Inc. Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros
WO2012041965A1 (en) 2010-09-29 2012-04-05 Universidad Nacional De Quilmes Process for producing dialkylphosphotriesters of nucleosides by enzymatic transesterification and deprotection thereof for producing nucleoside monophosphates
EP2640392B1 (en) 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
GB201107768D0 (en) 2011-05-10 2011-06-22 Univ Manchester Riboswitches
CN102286048A (zh) 2011-06-24 2011-12-21 吉林大学 4-氨基-6-(3-(3-溴苯基)苯基)-5-氰基-7-(β-L-呋喃木糖)吡咯并[2, 3-d]嘧啶、同类衍生物及用于制备抗肿瘤药物
WO2013044030A1 (en) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
WO2013071415A1 (en) 2011-11-15 2013-05-23 University Health Network Targeting the rb pathway for the prevention of cancer
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
CA2905306A1 (en) 2013-04-29 2014-11-06 Plasmia Biotech, S.L. Biocatalytic production of nucleoside analogues as active pharmaceutical ingredients

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538442A (ja) * 2020-08-24 2023-09-07 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用

Also Published As

Publication number Publication date
PH12018500263A1 (en) 2018-08-13
CN108026136A (zh) 2018-05-11
EP3331895B1 (en) 2020-07-29
WO2017024310A1 (en) 2017-02-09
US20250084119A1 (en) 2025-03-13
MX2018001073A (es) 2018-06-12
CA2992278A1 (en) 2017-02-09
US10407457B2 (en) 2019-09-10
US9708359B2 (en) 2017-07-18
US20200199167A1 (en) 2020-06-25
US9701706B2 (en) 2017-07-11
EP3331895A1 (en) 2018-06-13
EA201890454A1 (ru) 2018-07-31
US20170137454A1 (en) 2017-05-18
AU2016301188A1 (en) 2018-02-15
KR102630013B1 (ko) 2024-01-25
US11981700B2 (en) 2024-05-14
KR20180039666A (ko) 2018-04-18
US20220002335A1 (en) 2022-01-06
US10941175B2 (en) 2021-03-09
BR112018002399A2 (pt) 2018-09-25
US20170044202A1 (en) 2017-02-16
US20170253628A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
KR102630013B1 (ko) 항바이러스제로서 유용한 피롤로피리미딘 뉴클레오시드 및 그의 유사체
JP6043338B2 (ja) 抗ウイルス治療用の１’−置換ピリミジンｎ−ヌクレオシド類似体
AU2024205205A1 (en) Methods for treating SARS CoV-2 infections
CA3139977A1 (en) Peptidomimetics for the treatment of coronavirus and picornavirus infections
EP3181555B1 (en) Benzothiazole compounds and their pharmaceutical use
RU2599013C2 (ru) Способы и композиции для ингибирования полимеразы
JP6402259B2 (ja) 多環式カルバモイルピリドン化合物およびそれらの薬学的使用
EP3900717B1 (en) Vidofludimus for use in the treatment or prevention of viral diseases
CN117362344A (zh) 一类磷酸酯类化合物、其制备方法及应用
JP2025517992A (ja) デング感染の治療のための投薬レジメン
JP2016540776A (ja) 分枝鎖非環式ヌクレオシドホスホン酸エステルならびにその合成法および使用
CA2992278C (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
ES2829254T3 (es) Nucleósidos de pirrolopirimidina y análogos de los mismos útiles como agentes antivíricos
WO2021231784A1 (en) Perk inhibiting imidazolopyrazine compounds
EP4103567B1 (en) Spirocyclic inhibitors of hepatitis b virus
HK40062780A (en) Vidofludimus for use in the treatment or prevention of viral diseases
KR20220034049A (ko) B형 간염 바이러스의 옥살아미도-치환된 삼환형 억제제
EA045093B1 (ru) Производное n4-гидроксицитидина, содержащая его фармацевтическая композиция и связанные с этим противовирусные применения
NZ616732B2 (en) 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
HK1237770B (en) Benzothiazole compounds and their pharmaceutical use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190806

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190822